-
Health Commission: 12 newly diagnosed local cases in Jiangsu and Yunnan
Time of Update: 2021-07-27
As of 24:00 on July 21, according to reports from 31 provinces (autonomous regions and municipalities) and the Xinjiang Production and Construction Corps, there are currently 638 confirmed cases (including 16 severe cases), 87,140 cured and discharged cases, and 4,636 deaths.
-
All 13 volumes of "Chinese Medicinal Plants" published
Time of Update: 2021-07-27
Professor Liu Junyi, former dean of the School of Pharmacy of Peking University, pointed out in the preface that "Chinese Medicinal Flora" comprehensively, completely and systematically introduces the morphological classification, distribution, efficacy and application, chemical composition, pharmacological effects and use of medicinal plants in China.
-
Puli Pharmaceutical Etibatide Injection Obtained Drug Registration Approval
Time of Update: 2021-07-27
On July 25, Puli Pharmaceuticals announced that it had recently received a drug registration approval for eptifibatide injection issued by the State Food and Drug Administration.
It was approved for listing in Europe in July 1999 and is now under the responsibility of GlaxoSmithKline.
-
Over 60 new drugs have been approved for clinical use, and the outbreak of bispecific antibodies is imminent?
Time of Update: 2021-07-27
Dozens of double antibodies entered the clinic Last year, WuXi Biologics published an article that counted the global selection of bispecific antibody target combinations (see the figure below) .
-
Two innovative drugs are planned to be included in the priority review from Betta Pharmaceuticals and Cinda Bio
Time of Update: 2021-07-27
Screenshot source: CDE official websiteAccording to the press release issued by Cinda Biologics, the drug's marketing application in mainland China is based on an open, single-arm, multi-center Phase 2 study, which aims to undergo at least first-line systemic treatment in the past To evaluate the efficacy and safety of pemigatinib in patients with locally advanced, recurrent or metastatic cholangiocarcinoma who have failed, unresectable surgery with FGFR2 fusion or rearrangement .
-
Betteni's independent director Yao Ronghui resigns and Li Zhiwei nominates the candidate
Time of Update: 2021-07-27
Yao Ronghui applied to resign as an independent director of the company, and at the same time He resigned from the audit committee, remuneration and appraisal committee, and nomination committee of the company's board of directors, and did not hold any other positions in the company .
-
A new anti-gout drug has exploded!
Time of Update: 2021-07-27
The fastest research and development is Hengrui Medicine's SHR4640 tablets, which is currently undergoing phase III clinical trials in China and is expected to become the first domestically approved Class 1 new drug in the field of anti-gout .
-
Zhou Hong, President of Roche Pharmaceuticals China, resigns to Merck's vice president of market access, Bian Xin, to take over
Time of Update: 2021-07-27
At the same time, Merck announced that Zhou Hong will serve as the head of Merck Group Pharmaceutical and Health China and international markets.
-
Press conference of the State Council Information Office: Carry out scientific tracing with a scientific attitude
Time of Update: 2021-07-27
Combining the research results of various aspects such as clinical epidemiology, animal and environmental testing, the joint expert group finally determined four possibilities for the emergence of the virus: the direct spillover of zoonotic diseases is "probable to more likely"; introduction through intermediate hosts It is "more likely to very likely"; it is "possible" to introduce it through the cold chain.
-
National Medical Insurance Administration: Ensure that the cost of giving birth to three children is included in the payment scope of maternity insurance benefits
Time of Update: 2021-07-27
The National Medical Insurance Bureau requires that medical insurance departments in all regions should attach great importance to improving their political positions, actively adopt effective and efficient measures to ensure the implementation of the three-child reproductive treatment policy, and actively carry out positive publicity to enhance the sense of gain among the insured people .
-
New pattern!
Time of Update: 2021-07-27
After the implementation of the policies of "separation of licenses and licenses" and "removal of distance between pharmacies", industry competition has intensified, and ordinary people have benefited, while life in small pharmacies has become even more difficult .
-
Incomplete inventory of sky-high drugs
Time of Update: 2021-07-27
The same benefits of drugs mean that the unit price is higher, and the pharmaceutical companies need corresponding regular returns to cover the continuous research and development costs .
Different from the high-priced drugs listed above, the currently approved cell therapy product indications cannot be regarded as rare diseases.
-
PIC/S Release Data Reliability Guide (Full text download attached)
Time of Update: 2021-07-27
PIC/S PI 041-1 GOOD PRACTICESFORDATAMANAGEMENT ANDINTEGRITYINREGULATED GMP/GDPENVIRONMENTS Good practices for data management and integrity in a regulated GMP/GDP environment Because the original text is too long, friends who need the full text can download it as follows: Official original download https://picscheme.
-
Health Commission: 35 new confirmed cases on the 23rd, 13 local cases
Time of Update: 2021-07-27
The latest situation of the novel coronavirus pneumonia epidemic as of 24:00 on July 23 The latest situation of the novel coronavirus pneumonia epidemic as of 24:00 on July 23 The l
-
Retests of blood samples show that the new coronavirus may have spread in Italy
Time of Update: 2021-07-27
In November last year, researchers from the National Cancer Institute of Milan published a paper in the country’s Journal of Oncology, stating that they tested blood samples from 959 volunteers who participated in a lung cancer screening test from September 2019 to March 2020.
-
The joint research report on the traceability of the new coronavirus can withstand the test of history
Time of Update: 2021-07-27
According to Zeng Yixin, deputy director of the National Health Commission, on March 30 this year, the World Health Organization officially released the global traceability study of the new crown virus convened by the World Health Organization: a joint research report on the Chinese part.
-
The second-stage traceability investigation plan should not violate common sense and science
Time of Update: 2021-07-27
" China-WHO Joint Research Expert on New Coronavirus Traceability Liang Wannian, the Chinese leader of the group, introduced at the press conference that the joint expert group went to Wuhan Virus Institute for a more detailed understanding, communicated with relevant researchers, including relevant management personnel, and inspected the site, especially for its standardization process and management.
-
WHO: COVID-19 has "long-term and far-reaching" impact on mental health
Time of Update: 2021-07-27
The “Summit on the Impact of the New Crown Epidemic on the Mental Health and Related Service Institutions in Europe and the Response Measures” jointly organized by the WHO Regional Office for Europe and the Greek government was held from the 22nd to the 23rd .
-
Jiyu Pharmaceutical's SMO inhibitor approved in China
Time of Update: 2021-07-27
China National Medical Products Administration (NMPA) recently announced that a new class 5.
Public information shows that this is an SMO inhibitor that has been included in the priority review by the NMPA Drug Evaluation Center (CDE).
Screenshot source: NMPA official website
-
Health Commission: On the 24th, 32 newly diagnosed cases and 5 local cases were confirmed
Time of Update: 2021-07-27
The latest situation of the novel coronavirus pneumonia epidemic as of 24:00 on July 24 The latest situation of the novel coronavirus pneumonia as of 24:00 on July 24 The latest sit
